非小细胞肺癌“个体化”化疗研究进展  

Progress of clinical research in"tailor"chemotherapy for non-small-cell lung cancer

作　　者：程刚[1] 

机构地区：[1]卫生部北京医院肿瘤内科,100730

出　　处：《中国肺癌杂志》2008年第1期10-13,共4页Chinese Journal of Lung Cancer

摘　　要：非小细胞肺癌NSCLC的发病率和死亡率近年都呈上升趋势,化疗是有效的全身治疗,目前最好的联合方案其有效率仅为20%-40%。要进一步提高疗效就需要更合理,更准确的用药;而能否针对不同分子生物学特点的NSCLC进行药物疗效的预测是关键。近年来随着肿瘤分子生物学的发展,已发现ERCC1,RRM1,Beta-tubulin,BRCA1及胸苷酸合成酶(thymidylate synthetase,TS)的表达水平和化疗药物疗效及预后密切相关,并有可能成为预测疗效进行"个体化"化疗的重要因素。本文就这一领域的一些研究作一简单综述。The both incidence and mortality of non-small-cell lung cancer （NSCLC） have been obviously increasing in recent years, the chemotherapy is still one of the best systemic treatment with response rates of 20%-40% by different regimens. We still need more logical and more accuracy to use the agents against NSCLC if we try to improve the efficacy. Biological markers for predicting the efficacy based on different molecular characteristic of NSCLC is important. With the development of molecular biology in past years, we have realized the different expression of ERCC1, RRM1, Beta-tubuhn, BRCA1 and Thymidylate synthetase（TS）may be related to the efficacy of different chemotherapeutic agents and prognosis in NSCLC. So it is possible for predicting results of chemotherapeutic agents with those different markers, ＂tailor＂chemotherapy. This article is a clinical review in the fields.

关 键 词：非小细胞肺癌 化疗 个体化 ERCC1 RRM1 BETA-TUBULIN BRCA1 胸苷酸合成酶 

分 类 号：R734.2[医药卫生—肿瘤]